Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL699445 | 0.94 | OPRM1 (0.43) | OPRM1OGFRL1OPRL1KMT2ATRPA1 | |
| SCHEMBL701425 | 0.94 | OPRM1 (0.43) | OPRM1OGFRL1OPRL1KMT2ATRPA1 | |
| SCHEMBL698520 | 0.93 | OPRM1 (0.42) | OPRM1OGFRL1OPRL1KMT2ATRPA1 | |
| SCHEMBL700598 | 0.88 | OPRM1 (0.46) | OPRM1OGFRL1OPRL1KMT2ATRPA1 | |
| SCHEMBL700104 | 0.86 | OPRM1 (0.53) | OPRM1OGFRL1OPRL1KMT2ALPAR1 | |
| SCHEMBL698945 | 0.85 | OPRM1 (0.52) | OPRM1OGFRL1OPRL1KMT2ATRPA1 | |
| SCHEMBL698790 | 0.84 | OPRM1 (0.65) | OPRM1OGFRL1OPRL1KMT2ALPAR1 | |
| SCHEMBL700660 | 0.83 | OPRM1 (0.50) | OPRM1OGFRL1OPRL1KMT2ATRPA1 | |
| SCHEMBL2139650 | 0.83 | OPRM1 (0.69) | OPRM1OGFRL1OPRL1KMT2AOPRD1 | |
| SCHEMBL700789 | 0.82 | OPRM1 (0.51) | OPRM1OGFRL1OPRL1KMT2ATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124788-B2 | Spirocyclic cyclohexane compounds with analgesic activity | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | claimed |
| EP-2010531-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES WITH ANALGESIC PROPERTIES | GRUENENTHAL GMBH (DE) | 2011-08-17 | — | — | EP | claimed |
| US-20090111842-A1 | SPIROCYCLIC CYCLOHEXANE COMPOUNDS WITH ANALGESIC ACTIVITY | GRUENENTHAL GMBH (DE) | 2009-04-30 | — | — | US | claimed |
| EP-2010531-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVE WITH ANALGESIC PROPERTIES | Grünenthal GmbH (DE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007124903-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVE WITH ANALGESIC PROPERTIES | Grünenthal GmbH (DE) | 2007-11-08 | — | — | WO | claimed |
| US-8124788-B2 | Spirocyclic cyclohexane compounds with analgesic activity | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| EP-2010531-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES WITH ANALGESIC PROPERTIES | GRUENENTHAL GMBH (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-20090111842-A1 | SPIROCYCLIC CYCLOHEXANE COMPOUNDS WITH ANALGESIC ACTIVITY | GRUENENTHAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111842-A1 | SPIROCYCLIC CYCLOHEXANE COMPOUNDS WITH ANALGESIC ACTIVITY | OPRK1, OPRL1, OPRD1 | OPRM1 9/4885OGFRL1 163/4885OPRL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.